Infinimmune Is Betting the Best Antibody Has Already Been Made

The Alameda biotech searches human immune memory for drug candidates, then uses computation to improve them. Its first big test is eczema: two antibodies, $87 million in disclosed funding, and clinical studies planned for 2027.